Medical and Health Science Journal

  Previous Article | Back to Volume | Next Article
  Abstract | References | Citation | Download | Preview | Statistics
Volume 13
Issue 4
Online publication date 2012-12-15
Title Fluctuations of CD34 cells number in blood of cancer patients during final year of life
Author Alexey Shoutko, Lyudmila Ekimova, Viktor Mus, Valentina Sokurenko
The purpose of the work was the comparative study of dynamic relations between the fluctuation of survival rate and presence of hematopoietic progenitor cells in circulating blood of oncologic patients in the final months of their life. The registered associativity turbulence in the content of CD34 cells in a blood of the advanced oncologic patients and turbulence of probability of their death leads to the assumption that the reason for life’s cessation may be the abnormal morphogenic activity of young cells produced in the bone marrow toward the tumor tissues of the host,  as well as a lack of such activity toward the critical normal tissues. Thus, the cytotoxic, especially long-term, therapy of patients with advanced cancer may be timely even harmful for them and compromise the ultimate result of treatment.
The regimes of cytotoxic therapy of patients in cases of premature exhaustion of haematopoietic resource should be optimized based on individual periodicity of blood saturation with progenitor cells. The development of reliable and simple methods for  clinical monitoring of quickly changing prognosis of patients status  seems to become important aim of coming investigation. The data might be useful for optimization of regimes of cytotoxic therapy of individual patients in emergency.
Armstrong, A., Marengo, M., Oltean, S., Kemeny, G., Bitting, R., Turnbull, J., Herold, Ch., Marcom, P., George, D., Garcia-Blanco, M., 2011. “Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers,” Mol Cancer Res., Vol.9(8), pp.997-1007 

Begley, C., Ellis, L., 2012. “Drug development: Raise standards for preclinical cancer research,” Nature, Vol. 483, pp.531-33

Bochkareva, T., Ekimova, L., Nemkova, E., Sokurenko, V., Shutko, A., 2008. “Latent heterogeneity of prognosis among cancer patients,” Voprosy Onkologii, Vol.54(4), pp.480-82, Type: Journal Article, English Abstract (lang: rus) 

Cancer Therapy Evaluation Program, 1999. “Common Toxicity Criteria,”CTEP, April 30, pp.1-35

Drapeau, Ch., 2010. Cracking the Stem Cell Code, US: Sutton Hart Press
Dalakas, E., Newsome, P., Harrison, D., Plevris, J., 2005. “Hematopoietic stem cell trafficking in liver injury,” The FASEB Journal, Vol.19, pp.1225-231 

Fan, L., He, F., Liu, H., Zhu, J., Liu, Y., Yin, Z., Wang, L., Guo, Y., Wang, Z., Yan, Q., Huang, G., 2011.“CD133: A potential indicator for differentiation and prognosis of human cholangiocarcinoma,” BMC Cancer, Vol.11, pp.320-28

Fliedner, T., Graessle D., 2008. “Hematopoietic cell renewal system: Mechanisms of coping and failing after chronic exposure to ionizing radiation,” Radiation and Environmental Biophysics, Vol.47, pp.63-69

Folkman, J., 2004. “A novel anti-vascular therapy for cancer,” Cancer Biology and Therapy, Vol.3, pp.338-39

Goon, P., Lip, G., Stonelake, P., Blann, A., 2009. “Circulating endothelial cells and circulating progenitor cells in breast cancer: Relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index,” Neoplasia, Vol.11(8), pp.771-79

Heymach, J., Folkman, J., Kalluri, R., Deker R., 2010. “Tumor angiogenesis”, in Hong, W., Bast, R., Hait, W., Kufe, D., Pollack, R., Weichselbaum, R., Holland, J., Frei III, E.(Eds), “Holland Frei Cancer Medicine”, Part 2, “Scientific foundations of cancer”, Section1. “Cancer biology”, pp. 148-69

Ho, A., Wagner, W., Mahlknecht, U., 2005. “Stem cells and ageing,” European Molecular Biology Organization Reports, Vol.6, pp.35-38 

Hur, J., Yang, H.-M., Yoon, C.-H., Lee, C.-S., Park, K.-W., Kim, J.-H., Kim, T.-Y., Kim, J.-Y.,Kang, H.-J., Chae, I.-H., Oh, B.-H., 2007. “Identification of a novel role of T-cells in postnatal vasculogenesis,” Circulation, Vol.116, pp.1671-682 

Iinuma, H., Watanabe, T., Mimori, K., Adachi, M., Hayashi, N., Tamura, J., Matsuda, K., Fukushima, R., Okinaga, K., Sasako, M., and Mori, M., 2011. “Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer,” Cancer Sci., Vol.29(12), pp.1547-555 

Kucia, M., Ratajczak, J., Ratajczak, M., 2005. “Bone marrow as a source of circulating CXCR4 tissue commited stem cells,” Biol Cell, Vol.97, pp.133-46

Mineo, T., Ambrogi, V., Baldi, A., Rabitti, C., Vincenzi, B.,  Bollero, P., Tonini, G., 2004. “Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer,” J. Clin. Pathol., Vol.57(6), pp.591-97 

Morgan, G., Ward, R., Barton, M., 2004. “The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies,” Clin oncol (R Coll Radiol), Vol.16(8), pp.549-60 

Propert, K., Andersen, J., 1988. “Assesing the effect of  toxicity on prognosis,” J. Clin. Oncology, Vol.6(5), pp.868-70

Reihelt, H., Barz, D., Thude, H., 2009. “CD34 and CD133 primitive stem cells in peripheral blood: Considering gender, age, and smoking,” Transfus Med Hemother., Vol.36, pp.129-34 

Shoutko, A., Shatinina, N., “Chronic cancer - could it’s be?,” 6 Annual Conference of MSAIMA, November 25, 1998, Tel-Aviv

Shutko, A., Akushevich, I., Ekimova, L., Karamullin, M., Yashin, A., 2008. “On stable fluctuation in survival of treated breast cancer patient,” Radioprotection (36th annual meeting of the European Radiation Research Society),Vol.43(5), Article Number 233

Trempus, C., Morris, R., Ehinger, M., Elmore, A., Bortner, C., Ito, M., Cotsarelis, G., Nijhof, J., Peckham, J., Flagler, N., Kissling, G., Humble, M., King, L., Adams, L., Desai, D., Amin, Sh., Tennant R., 2007. “CD34 expression by hair follicle stem cells is required for skin tumor development in mice,” Cancer Res, Vol.67(9), pp.4173-181

U.S.Department of health and human services, National Institute of Health, National Cancer Institute, 2006. “Common Terminology Criteria for Adverse Events (CTCAE) Version 3”, U.S.D.H.H.S., NIH, NCI, August 9, pp.1-71

Vernier”Graphical Analisis, 3.1 DemoVersion, Texas Instruments. 2002
Weidt, C., Niggemann, B., Kasenda, B., Drell, T., Zänkerand, K., Dittmar, T., 2007. “Stem cell migration: A quintessential stepping stone to successful therapy,” Current Stem Cell Research & Therapy, Vol.2, pp. 89-103

Wright, D., Wagers, A., Gulati, A., Johnson, F., Weissman, I., 2001. “Physiological migration of hematopoietic stem and progenitor cells,” Science, Vol.294, pp.1933-936

Yamaura, K., Matsuzawa, T., 1979. “Tumor regrowth after irradiation: An experimental approach,” Int J Radiat Biol, Vol.35(3), pp.201-19

Yu, X., Lin, Y., Yan, X., Tian, Q., Li, L., Lin, E., 2011. “CD133 stem cells, and cancer stem cells: Myth or reality?,” Curr Colorectal Cancer Rep., Vol.7(4), pp.253-59

Keywords Cancer, survival, life span, monthly risk of a mortality, periodicity, blood stem cells, approximation
Pages 7-13
Download Full PDF Download
  Previous Article | Back to Volume | Next Article
Search in articles
Journal Published articles
MHSJ 940
Journal Hits
MHSJ 2308182
Journal Downloads
MHSJ 17101
Total users online -